Filing Flows › DexCom (DXCM) › Q3 2026 › vs Q3 2025
DexCom (DXCM) Q3 2026 vs Q3 2025 (year over year)
DexCom's revenue rose $135M (+11%) from $1.2B in Q3 2025 to $1.3B in Q3 2026. Gross margin 64.3% against 60.5% (+3.8 pts).
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 64.3% | 60.5% | +3.8 pts |
| Operating margin | 24.3% | 20.1% | +4.3 pts |
| Net margin | 20.5% | 23.5% | -3.0 pts |
| Free cash flow margin | 20.3% | 47.9% | -27.6 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $135M | +11% |
| Gross profit | $864M | $731M | $133M | +18% |
| Cost of revenue | $480M | $478M | $2.2M | +0.5% |
| Other income, net | $7.5M | $110M | −$102M | -93% |
| Operating profit | $327M | $242M | $84.7M | +35% |
| Operating expenses | $537M | $489M | $48.3M | +10% |
| Pre-tax earnings | $335M | $352M | −$17.6M | -5% |
| Research & development | $162M | $158M | $4.1M | +3% |
| SG&A | $376M | $331M | $44.2M | +13% |
| Net earnings | $275M | $284M | −$8.7M | -3% |
| Income tax | $59.6M | $68.5M | −$8.9M | -13% |
| Depreciation & amortization | $74.5M | $63.6M | $10.9M | +17% |
| Share-based compensation | $36.8M | $45.1M | −$8.3M | -18% |
| Working capital & other | $60.8M | −$267M | $328M | — |
| Operating cash flow | $326M | $660M | −$334M | -51% |
| Free cash flow (OCF − capex) | $273M | $579M | −$307M | -53% |
| Capital expenditures | $52.9M | $80.5M | −$27.6M | -34% |
Questions
How much did DexCom's revenue grow year over year in Q3 2026?
DexCom's revenue rose $135M (+11%) from $1.2B in Q3 2025 to $1.3B in Q3 2026. Gross margin 64.3% against 60.5% (+3.8 pts).